STRO-1+ Cell Therapy for Inflammatory Neurological Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory neurological diseases such as multiple sclerosis and systemic lupus erythematosus are only moderately effective and often come with undesirable side effects, failing to address the underlying immune response and promote remyelination.
Innovation Solution
Administration of STRO-1+ multipotential cells and their progeny, or soluble factors derived therefrom, to reduce immune response severity, prevent relapses, and promote tolerance in inflammatory neurological diseases by increasing regulatory T cells and administering them systemically or directly to the central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If high-dose corticosteroids are administered to treat acute MS relapses, then relapse duration is shortened, but the degree of recovery and long-term disease course are not improved
Solution Approach 1:
The patent uses cytokines (such as IL-2, IL-4, IL-10, TGF-beta) and growth factors as intermediary substances to modulate the immune response and promote remyelination. These mediators bridge the gap between suppressing inflammation and promoting long-term recovery, addressing both the acute relapse duration and long-term disease course improvement without relying solely on high-dose corticosteroids.
Solution Approach 2:
The patent changes the therapeutic parameters by administering multiple cytokines and growth factors in specific combinations and sequences, rather than using a single high-dose corticosteroid. This multi-parameter approach includes controlling timing, dosage, and type of each factor to optimize both short-term relapse management and long-term disease modification, including promotion of remyelination.
2Reliability
If disease-modifying therapies are administered to lower relapse rate and reduce new lesions, then clinical relapse rate is reduced, but remyelination is not promoted and disease progression is merely retarded
Solution Approach 1:
The patent merges multiple therapeutic mechanisms by combining disease-modifying therapies with remyelination-promoting factors. The composition includes cytokines and growth factors that simultaneously suppress inflammation (reducing relapse rate) and promote oligodendrocyte differentiation and myelin synthesis (promoting remyelination), thereby addressing both concerns in a unified therapeutic approach.
Solution Approach 2:
The patent creates a composite therapeutic composition containing multiple biologically active substances (cytokines, growth factors, and other modulators) that work synergistically. This composite approach combines the disease-modifying effects with remyelination-promoting effects, achieving both relapse rate reduction and active remyelination promotion that neither component could achieve alone.
3Object-affected harmful factors
If immunosuppressive drugs or corticosteroids are administered to treat inflammatory neurological diseases, then immune response is suppressed, but infection risk and adverse side effects increase
Solution Approach 1:
The patent segments the immune modulation function into multiple specific cytokines and growth factors, each targeting particular aspects of the immune response. Rather than using broad-spectrum immunosuppressants that suppress all immune functions (causing infection risk), the composition uses specific factors (e.g., IL-10 for anti-inflammatory effects, TGF-beta for immunoregulation) that selectively modulate pathological immune responses while preserving protective immunity.
Solution Approach 2:
The patent incorporates feedback mechanisms through cytokines that regulate immune responses in a controlled manner. The composition includes factors that can sense and respond to the inflammatory state, providing negative feedback to suppress excessive immune activation while maintaining baseline immune function. This feedback-controlled approach reduces the need for strong immunosuppression and minimizes infection risk and side effects.
Data Source
AI summary
The present disclosure provides a method for treating an inflammatory neurological disease comprising administering a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.